Order Article Reprints

Vergez F, Nicolau-Travers M-L, Bertoli S, Rieu J-B, Tavitian S, Bories P, Luquet I, De Mas V, Largeaud L, Sarry A, et al. CD34⁺CD38⁻CD123⁺ Leukemic Stem Cell Frequency Predicts Outcome in Older Acute Myeloid Leukemia Patients Treated by Intensive Chemotherapy but Not Hypomethylating Agents. Cancers. 2020; 12(5):1174. https://doi.org/10.3390/cancers12051174

Vergez, François, Marie-Laure Nicolau-Travers, Sarah Bertoli, Jean-Baptiste Rieu, Suzanne Tavitian, Pierre Bories, Isabelle Luquet, Véronique De Mas, Laetitia Largeaud, Audrey Sarry, and et al. 2020. "CD34⁺CD38⁻CD123⁺ Leukemic Stem Cell Frequency Predicts Outcome in Older Acute Myeloid Leukemia Patients Treated by Intensive Chemotherapy but Not Hypomethylating Agents" Cancers 12, no. 5: 1174. https://doi.org/10.3390/cancers12051174

Vergez, F., Nicolau-Travers, M.-L., Bertoli, S., Rieu, J.-B., Tavitian, S., Bories, P., Luquet, I., De Mas, V., Largeaud, L., Sarry, A., Huguet, F., Delabesse, E., Bérard, E., & Récher, C. (2020). CD34⁺CD38⁻CD123⁺ Leukemic Stem Cell Frequency Predicts Outcome in Older Acute Myeloid Leukemia Patients Treated by Intensive Chemotherapy but Not Hypomethylating Agents. Cancers, 12(5), 1174. https://doi.org/10.3390/cancers12051174